Ariants of 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of brain diseases

Abstract

The present invention relates to 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of disorders caused by delipidation of neural tissue. Specific aspects relate to certain administration or dosing patterns, routes of administration. In one embodiment of the present invention is the invention Multiple Sclerosis (MS) or an MS associated disease.

1 . A method of treating or ameliorating Multiple Sclerosis (MS) or an MS associated disease comprising administering an R(+)-etomoxir ethyl ester with the chemical formula R(+)-2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid ethyl ester to a person in need thereof at an amount of 80 mg/day. 
     
     
         2 - 10 . (canceled) 
     
     
         11 . The method according to  claim 1 , wherein the 80 mg/day R(+)-etomoxir ethyl ester is administered to said person at two times of 40 mg/each. 
     
     
         12 . The method according to  claim 1 , wherein the MS associated disease is selected from the group consisting of Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Optic Neuritis (ON), Clinically Isolated Syndrome (CIS), Amyotrofic lateral sclerose (ALS), Neuromyelitis optica (NMO), depression, and Acute Optic Neuritis (AON). 
     
     
         13 . The method according to  claim 1 , wherein said R(+)-etomoxir ethyl ester is formulated in a pharmaceutical composition. 
     
     
         14 . The method of  claim 1 , wherein said R(+)-etomoxir ethyl ester is formulated in a pharmaceutically effective amount. 
     
     
         15 . The method of  claim 1 , wherein said R(+)-etomoxir ethyl ester is formulated for oral administration. 
     
     
         16 . The method of  claim 15 , wherein said R(+)-etomoxir ethyl ester is formulated in a tablet or capsule. 
     
     
         17 . The method of  claim 1 , wherein the MS associated disease is Secondary Progressive MS (SPMS). 
     
     
         18 . The method of  claim 1 , wherein the treatment or amelioration is measured as a statistically significant change in Normalized Brain Volume (NBV) over a period of 6 months compared to placebo. 
     
     
         19 . The method of  claim 1 , wherein the treatment or amelioration downregulates one or more of IL17a, TNFa, or IFNg.